Here are what the editors at HealthDay consider to be the most important developments in Hematology & Oncology for April 2019. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice. Targeted Therapy Promising for Rare Hematologic […]
Read More
ZURICH (Reuters) – Novartis’s Sandoz division has struck a deal with Taiwan’s...
Read More
Higher doses of nicotine gum and patches also may increase quit rate
Read More
Tagraxofusp seems effective for treating blastic plasmacytoid dendritic-cell neoplasm
Read More
Two-year and three-year biochemical progression-free survival rate of 100 percent for low-risk disease
Read More
By Deena Beasley (Reuters) – The U.S. Centers for Medicare and Medicaid Services will...
Read More
By Carolyn Crist (Reuters Health) – Cancer patients and survivors are often at high risk of...
Read More
Drug combination approved for advanced renal cell carcinoma based on findings from KEYNOTE-426
Read More
Patients who visit ED at alternative hospital or noncancer center at increased risk for worse outcomes
Read More
(Reuters) – The U.S. Food and Drug Administration has approved Merck & Co Inc’s...
Read More
Rate of hepatic tumors higher among children conceived via IVF
Read More
By Linda Carroll (Reuters Health) – In many parts of the world there are not enough...
Read More
By Lisa Rapaport (Reuters Health) – Most teens and young adults with cancer want a voice in...
Read More
Variation seen in treatment by cancer type, age, insurance, and facility type
Read More
Instrumental activities of daily living dependency, mortality linked in seniors with hematologic cancer
Read More
Treatment-free remission maintained in 14 of 21 patients who discontinued tyrosine kinase inhibitors
Read More
Prevalence higher for advanced adenomas, advanced serrated lesions, serrated polyposis syndrome
Read More
(Reuters) – Johnson & Johnson’s drug Balversa won U.S. approval as the first...
Read More
Balversa indicated for treatment of bladder cancer with FGFR3 or FGFR2 genetic alteration
Read More
One-third of cancer patients, survivors use CAM; 29.3 percent do not disclose CAM use to their doctor
Read More
